Boehringer Ingelheim’s BI 690517 shows up to 39.5% albuminuria reduction in Phase II trial

Boehringer Ingelheim has revealed promising results from its 14-week Phase II trial for BI 690517, a novel selective aldosterone synthase inhibitor. The data highlights a ... Read More